Pediatrics: Diagnosis of neuroblastoma

Seminars in Nuclear Medicine

Volumn 41, Issue 5, 2011, Pages 345-353

  Sharp, Susan E ^a   Gelfand, Michael J ^a   Shulkin, Barry L ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; 3 IODOBENZYLGUANIDINE F 18; 3' FLUOROTHYMIDINE F 18; ADRENALIN C 11; DIHYDROXYPHENYLALANINE F 18; FLUOROBENZYLGUANIDINE F 18; FLUORODEOXYGLUCOSE; FLUORODOPAMINE C 11; HYDROXYEPHEDRINE C 11; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CHILD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; INTERMETHOD COMPARISON; NEUROBLASTOMA; PEDIATRICS; RADIATION DOSE DISTRIBUTION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNITED STATES;

3-IODOBENZYLGUANIDINE; ANIMALS; BONE AND BONES; CHILD; FLUORODEOXYGLUCOSE F18; HUMANS; NEUROBLASTOMA; PEDIATRICS; RADIOPHARMACEUTICALS;

EID: 79960907344     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2011.05.001     Document Type: Review

References (84)

1. Lonergan GJ, Schwab CM, Suarez ES, et al: Neuroblastoma, ganglion-uroblastoma, and ganglioneuroma: Radiologic-pathologic correlation. RadioGraphics 22:911-934, 2002
2. DuBois SG, Kalika Y, Lukens JN, et al: Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol/Oncol 21:181-189, 1999 (Pubitemid 30306028)
3. Kaatsch P: Epidemiology of childhood cancer. Cancer Treat Rev 36:277-285, 2010
4. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993 (Pubitemid 23228250)
5. Monclair T, Brodeur GM, Ambros PF, et al: The International Neuroblastoma Risk Group (INRG) staging system: An INRG task force report. J Clin Oncol 27:298-303, 2009
6. London WB, Castleberry RP, Matthay KK, et al: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the children's Oncology Group. J Clin Oncol 23:6459-6465, 2005 (Pubitemid 46190236)
7. George RE, London WB, Cohn SL, et al: Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 23:6466-6473, 2005 (Pubitemid 46190237)
8. Schmidt ML, Lal A, Seeger RC, et al: Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group study. J Clin Oncol 23:6474-6480, 2005 (Pubitemid 46190238)
9. Alvarado CS, London WB, Look AT, et al: Natural history and biology of stage A neuroblastoma: A Pediatric Oncology Group study. J Pediatr Hematol/Oncol 22:197-205, 2000 (Pubitemid 32268303)
10. Perez CA, Matthay KK, Atkinson JB, et al: Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A Children's Cancer Group study. J Clin Oncol 18:18-26, 2000 (Pubitemid 30036332)
11. Nickerson HJ, Matthay KK, Seeger RC, et al: Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study. J Clin Oncol 18:477-486, 2000 (Pubitemid 30078529)
12. Hero B, Simon T, Spitz R, et al: Localized infant neuroblastomas often show spontaneous regression: Results of the prospective trials NB95-S and NB97. J Clin Oncol 26:1504-1510, 2008
13. Matthay KK, Perez C, Seeger RC, et al: Successful treatment of stage III neuroblastoma based on prospective biologic staging: A children's Cancer Group study. J Clin Oncol 16:1256-1264, 1998 (Pubitemid 28175737)
14. Schmidt ML, Lukens JN, Seeger RC, et al: Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective children's Cancer Group study. J Clin Oncol 18:1260-1268, 2000 (Pubitemid 30159844)
15. Baker DL, Schmidt ML, Cohn SL, et al: Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 363:1313-1323, 2010
16. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341:1165-1173, 1999 (Pubitemid 29480654)
17. Matthay KK, Reynolds CP, Seeger RC, et al: Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's Oncology Group study. J Clin Oncol 27:1007-1013, 2009
18. Kushner BH: Neuroblastoma: A disease requiring a multitude of imaging studies. J Nucl Med 45:1172-1188, 2004
19. Smets LA, Loesberg C, Janssen M, et al: Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 49:2941-2944, 1989 (Pubitemid 19148630)
20. Smets LA, Janssen M, Metwally E, et al: Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem Pharmacol 39:1959-1964, 1990 (Pubitemid 20187332)
21. Vik TA, Pfluger T, Kadota R, et al: (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer 52:784-790, 2009
22. Heyman S, Evans AE, D'Angio GJ: I-131 metaiodobenzylguanidine: Diagnostic use in neuroblastoma patients in relapse. Med Pediatr Oncol 16:337-340, 1988 (Pubitemid 18265424)
23. Biasotti S, Garaventa A, Villavecchia GP, et al: False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 35:153-155, 2000
24. Wieland DM, Swanson DP, Brown LE, et al: Imaging the adrenal medulla with an 131I-labeled antiadrenergic agent. J Nucl Med 20:155-158, 1980 (Pubitemid 9129566)
25. Treuner J, Feine U, Niethammer D, et al: Scintigraphic imaging of neuroblastoma with 131I-iodobenzylguanidine. Lancet 8372:333-334, 1984
26. Geatti O, Shapiro B, Sisson JC, et al: Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: Preliminary experience in ten cases. J Nucl Med 26:736-742, 1985 (Pubitemid 16005495)
27. Gelfand MJ: I-123-MIBG and I-131-MIBG imaging in children with neuroblastomas [abstract]. J Nucl Med 37s:35, 1996
28. Gelfand MJ, Parisi MT, Treves ST: Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med 52:318-322, 2011
29. Paltiel HJ, Gelfand MJ, Elgazzar AH, et al: Neural crest tumors: I-123 MIBG imaging in children. Radiology 190:117-121, 1994
30. Bonnin F, Lumbroso J, Tenenbaum F, et al: Refining interpretation of MIBG scans in children. J Nucl Med 35:803-810, 1994 (Pubitemid 24151215)
31. Okuyama C, Sakane N, Yoshida T, et al: (123)I- or (125)I- metaiodobenzylguanidine visualization of brown adipose tissue. J Nucl Med 43:1234-1240, 2002 (Pubitemid 34988772)
32. Okuyama C, Ushijima Y, Kubota T, et al: 123I-metaiodobenzylguanidine uptake in the nape of the neck of children: Likely visualization of brown adipose tissue. J Nucl Med 44:1421-1425, 2003 (Pubitemid 39663354)
33. Wood DE, Gilday DL, Eng B, et al: Stable iodine requirements for thyroid gland blockage of iodinated radiopharmaceuticals. J Can Assoc Radiol 25:295-296, 1974
34. Gelfand MJ, Elgazzar AH, Kriss VM, et al: Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 35:1753-1757, 1994 (Pubitemid 24346793)
35. Rufini V, Fisher GA, Shulkin BL, et al: Iodine-123-MIBG imaging of neuroblastoma: Utility of SPECT and delayed imaging. J Nucl Med 37:1464-1468, 1996 (Pubitemid 26321623)
36. Serafini A, Heiba SI, Tumeh SS, et al: Influence of SPECT on interpretation of 123I-mIBG scintigraphy in patients with known or suspected pheochromocytoma and neuroblastomas [abstract]. J Nucl Med 49s:239, 2008
37. Rozovsky K, Koplewitz BZ, Krausz Y, et al: Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol 190:1085-1090, 2008 (Pubitemid 351571524)
38. Bar-Sever Z, Steinmetz A, Ash S, et al: The role of MIBG SPECT/CT in children with neuroblastomas [abstract]. J Nucl Med 49s:84, 2008
39. Sharp SE, Gelfand MJ: Utility of SPECT/CT imaging in neuroblastomas [abstract]. J Nucl Med 50s:52, 2009
40. Fukuoka M, Taki J, Mochizuki T, et al: Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/ paraganglioma and neuroblastoma. Clin Nucl Med 36:1-7, 2011
41. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993 (Pubitemid 23228250)
42. Suc A, Lumbroso J, Rubie H, et al: Metastatic neuroblastoma in children older than one year: Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 77:805-811, 1996 (Pubitemid 26055409)
43. Ladenstein R, Philip T, Lasset C, et al: Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953-965, 1998 (Pubitemid 28108728)
44. Perel Y, Conway J, Kletzel M, et al: Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol/Oncol 21:13-18, 1999 (Pubitemid 29131988)
45. Schmidt M, Simon T, Hero B, et al: The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97. Eur J Cancer 44:1552-1558, 2008
46. Taggart DR, Han MM, Quach A, et al: Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 27:5343-5349, 2009
47. Kushner BH, Kramer K, Modak S, et al: Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 27:1041-1046, 2009
48. Ady N, Zucker JM, Asselain B, et al: A new 123I-MIBG whole body scan scoring method - Aplication to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 31:256-261, 1995
49. Frappaz D, Bonneu A, Chauvot P, et al: Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol 34:237-241, 2000 (Pubitemid 30176598)
50. Hero B, Hunneman DH, Gahr M, et al: Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol 36:220-223, 2001
51. Matthay KK, Edeline V, Lumbroso J, et al: Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21:2486-2491, 2003 (Pubitemid 46606329)
52. Katzenstein HM, Cohn SL, Shore RM, et al: Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 22:3909-3915, 2004 (Pubitemid 41079872)
53. Messina JA, Cheng SC, Franc BL, et al: Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 47:865-874, 2006 (Pubitemid 44656106)
54. Lewington V, Bar-Sever Z, Lynch T, et al: Development of a new, semiquantitative I-123 mIBG reporting method in high risk neuroblastoma. Eur J Nucl Med Mol Imaging 36:334, 2009
55. Matthay KK, Shulkin B, Ladenstein R, et al: Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: A report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 102:1219-1326, 2010
56. Stark DD, Mos AA, Brasch RC, et al: Neuroblastoma: Diagnostic imaging and staging. Radiology 148:101-105, 1983 (Pubitemid 13107790)
57. Stark DD, Mos AA, Brasch RC, et al: Recurrent neuroblastoma: The role of CT and alternate imaging tests. Radiology 148:107-112, 1983 (Pubitemid 13107791)
58. Golding SJ, McElwain TJ, Husband JE: The role of computed tomography in the management of children with advanced neuroblastoma. Br J Radiol 57:661-666, 1984 (Pubitemid 14053188)
59. Siegel MJ, Ishwaran H, Fletcher BD, et al: Staging of neuroblastoma at imaging: Report of the Radiology Diagnostic Oncology Group. Radiology 223:168-175, 2002 (Pubitemid 34258205)
60. Hogosson C, Nyman R, Jorulf H, et al: Imaging of abdominal neuroblastoma in children. Acta Radiol 40:534-542, 1999 (Pubitemid 129567267)
61. Sofka CM, Semelka RC, Kelekis NL, et al: Magnetic resonance imaging of neuroblastoma using current techniques. Magn Reson Imaging 17:193-198, 1999 (Pubitemid 29053177)
62. Slovis TL, Meza MP, Cushing B, et al: Thoracic neuroblastoma: What is the best imaging modality for evaluating extent of disease? Pediatr Radiol 27:273-275, 1997 (Pubitemid 27135424)
63. Tanabe M, Takahashi H, Ohnuma N, Iwai J, Yoshida H: Evaluation of bone marrow metastasis of neuroblastoma and changes after chemotherapy by MRI. Med Pediatr Oncol 21:54-59, 1993 (Pubitemid 23018177)
64. Tanabe M, Ohnuma N, Iwai J, et al: Bone marrow metastasis of neuroblastoma analyzed by MRI and its influence on prognosis. Med Pediatr Oncol 24:292-299, 1995
65. Lebtahi N, Gudinchet F, Nenadov-Beck M, et al: Evaluating bone marrow metastasis of neuroblastoma with iodine-123-MIBG scintigraphy and MRI. J Nucl Med 38:1389-1392, 1997 (Pubitemid 27386197)
66. Pfluger T, Schmied C, Porn U, et al: Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol 181:1115-1124, 2003 (Pubitemid 37151800)
67. Gordon I, Peters AM, Gutman A, et al: Skeletal assessment in neuroblastoma - the pitfalls of iodine-123-MIBG scans. J Nucl Med 31:129-134, 1990 (Pubitemid 20059210)
68. Shulkin BL, Shapiro B, Hutchinson RJ: Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma. J Nucl Med 33:1735-1740, 1992
69. Englaro EE, Gelfand MJ, Harris RE, et al: I-131 MIBG imaging after bone marrow transplantation for neuroblastoma. Radiology 182:515-520, 1992
70. Shulkin BL, Hutchinson RJ, Castle VP, et al: Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 199:743-750, 1996
71. 18F-FDG PET in neuroblastoma. J Nucl Med 50:1237-1243, 2009
72. Papathanasiou ND, Gaze MN, Sullivan K, et al: 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: Diagnostic comparison and survival analysis. J Nucl Med 52:519-525, 2011
73. Kushner BH, Yeung HW, Larson SM, et al: Extending positron emission tomography scan utility to high-risk neuroblastoma: Fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 19:3397-3405, 2001 (Pubitemid 32642193)
74. Colavolpe C, Guedj E, Cammilleri S, et al: Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer 51:828-831, 2008
75. McDowell HM, Losty P, Barnes N, et al: Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative [letter]. Pediatr Blood Cancer 52:552, 2009
76. Franzius C, Hermann K, Weckesser M, et al: Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: Feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med 47:1635-1642, 2006 (Pubitemid 47545029)
77. Shulkin BL, Wieland DM, Baro ME, et al: PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 37:16-21, 1996 (Pubitemid 26125958)
78. Shulkin BL, Wieland DM, Castle VP, et al: Carbon-11 epinephrine PET imaging of neuroblastomas [abstract]. J Nucl Med 40s:129, 1999
79. Tzen K, Wang L, Lu M: Characterization of neuroblastic tumors using F-18 DOPA PET [abstract]. J Nucl Med 48s:117, 2007
80. Valentiner U, Haane C, Peldschus K, et al: 18FFDG and [18F]FLT PET-CT and MR imaging of human neuroblastoma in a SCID mouse xenograft model. Anticancer Res 28:2561-2568, 2008
81. Krieger-Hinck N, Gustke H, Valentiner U, et al: Visualisation of neuroblastoma growth in a Scid mouse model using [18F]FDG and [18F]FLT-PET. Anticancer Res 26:3467-3472, 2006 (Pubitemid 44701524)
82. Vaidyanathan G, Zhao XG, Strickland DK, et al: No-carrier-added iodine-131-FIBG: Evaluation of an MIBG analog. J Nucl Med 38:330-334, 1997 (Pubitemid 27061621)
83. Vaidyanathan G, Affleck DJ, Zalutsky MR: Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 36:644-650, 1995
84. Vaidyanathan G, Affleck DJ, Zalutsky MR: (4-[18F]fluoro-3-iodobenzyl) guanidine, a potential MIBG analogue for positron emission tomography. J Med Chem 37:3655-3662, 1994 (Pubitemid 24334620)